Erlend B. Smeland and Jan Delabie co-author Nature article on BCR signalling

Smeland (left) and Delabie
Smeland (left) and Delabie

Erlend B. Smeland from the Department of Immunology and Jan Delabie from the Division of Pathology co-author an article published in the January 7 issue of Nature (impact factor 31.43), entitled "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma".

About the study:

A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying immunoglobulin genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed. Here the authors describe a form of 'chronic active' BCR signalling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).

 

Links:


Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. (link to PubMed)
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Nature. 2010 Jan 7;463(7277):88-92.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma (link to Nature)



Erlend B. Smeland's group: Lymphomas & Lymphocyte biology

Department of Immunology

Institute for Cancer Research

Division of Pathology